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Table 1. Clinical evolution  CIBMTR Pattern
Clinical Evolution Evaluation Method Cibmtr Pattern
Glucose 5 192mg/dL Acquired knowledgment + lab report Diabetes / hyperglycemia
Skin damage Physician and data manager discussion + lab report + acquired
knowledgment
Acute Skin GVHD, overall maxim grade II, stage 2
(25-50% of skin surface)
Mouth / GI Chronic GVHD Physician and data manager discussion + lab report + acquired
knowledgment
Chronic GVHD progressive, maximum grade: extensive,
overall severity: severe
Unremarkable mouth lichen Physician and data manager discussion + acquired knowledgment Are symptoms of chronic GVHD still present on the date
of actual contact?
Pleural effusion /
basilar consolidation
Physician and data manager discussion + acquired knowledgment Did the recipient develop non-infectious pulmonary
abnormalities?
RSV+ Lab report + acquired knowledgment Organism: RSV, Infection site: sinuses, date of diagnosis
Moderate ascites Physician and data manager discussion + lab report + acquired
knowledgment
Non-infectious liver toxicity (excluding GVHD)
S190 Oral Presentationspossible to get a conclusively and directly interpretation to be re-
ported on the standard CIBMTR data pattern.
Method: Study of a related allogeneic transplant case that we were
asked to do the Comprenhesive Report Form.
Case: Male, 53 years-old, MDS, HSCT infusion: 06/20/2009,
PBSC, HLA-identical sibling, Bu 1 Flu, ANC recovery: 05/07/
2009 and platelet recovery: 07/10/2009.
Results:Analyzing the chart, it’s seen that the interpretation of writ-
ten clinical data to the standard official CIBMTR forms requires
more than generalized information that are easily understood by
the clinical staff with their real and daily involvement with them
and the experience of practicing medicine. Data managers have
a ‘‘virtual relationship’’ with patients, no personal contact with
them and without scientific knowledgment to interpret certain infor-
mation and reports. What was concluded is that more detailed the
clinical outcome in the patient records, more support of clinical staff
and more acquired knowledgment by data managers, greater the ef-
ficiency in reporting data with a high degree of fidelity.
Feedback:During the relationship’s period between our Transplant
Center and CIBMTR we had a positive evolution of the way to deal
with transplant data. Physician’s and data managers’ relation had
global gains to our Center, working with the clinical outcome as
the primary source of data to be consulted and having footing for
this. The multidisciplinary team’s integration and the effort of the
medical directors, gave the data managers (including database per-
sonnel and a nurse) a day-by-day know-how to read clinical data
(not to interpret it, but the transcript it to CIBMTR standard) and
thus, gradually, the intervention of medical staff shall not be so nec-
essary. That is, reporting data to CIBMTR spawned to a natural evo-
lution of our Transplant Center, of the team (physicians, data
managers and nurse) and of the description and interpretation of
clinical information, resulting in the reliability of data, generating
a solid basis for prospective studies.99
PUBLICATION BIAS IN BLOOD AND MARROW TRANSPLANTATION: AN
ANALYSIS OF THE TANDEM MEETING ABSTRACTS
Paulson, K.1, Saeed, M.1, Mills, J.2, Cuvelier, G.D.E.1, Kumar, R.1,
Morcombe, K.1, Ramesar, K.1, Robinson, T.1, Szwajcer, D.1, Wall, D.1,
Watral, W.1, Seftel, M.D.1 1CancerCare Manitoba, University of Man-
itoba, Winnipeg, MB, Canada; 2Northwestern University, Chicago, IL
Background:Research studies presented in abstract formmay never
be fully published. In other areas of medicine, abstracts with positive
results are more likely to be published than negative studies, leading
to publication bias. There are limited data about the presence of pub-
lication bias in the field of blood andmarrow transplantation (BMT).
Methods: All abstracts presented at the 2006 CIBMTR/ASBMT
Tandem Meeting were categorized based on type of study (clinical
prospective or retrospective, translational, basic science, case report,
or review), and whether the results were positive, negative, or not
stated. An abstract was categorized as positive if it validated the au-
thors’ hypothesis, or if it showed that a new treatment, diagnostic
test, or procedure was useful. Two authors reviewed each abstract,
and a third author reviewed disagreements (if present). To determine
publication status, each abstract was searched on the MEDLINE
database by first and last authors.Results: 501 abstractswere reviewed. 217were published, giving a pub-
lication rate of 43%.Median time fromabstract presentation to full pub-
licationwas 19months (range 1 - 41months). 52.5%of all abstractswere
published in three journals - Biology of Blood and Marrow Transplan-
tation (19.8%), Blood (17.5%), or Bone Marrow Transplantation
(15.2%). The remaining 47.5%were published in 53 different journals,
with no one journal having more than 3% of published abstracts. Ab-
stracts that were positive were more likely to be published (50.1%)
than those that were negative (33%) or not stated (29.7%) (p5 0.001).
Clinical studies (retrospective or prospective) and translational/basic sci-
encestudiesweremore likely tobepublished thancase reportsorprimar-
ily descriptive studies (p5 0.001). Specifically, 48.5% of clinical studies
and 56.9% of basic science or translational studies were published, but
only 7.1% of descriptive or case reports were published.
Conclusion: Publication bias does exist in the field of BMT, with
positive abstracts significantly more likely to be published than neg-
ative abstracts. Full publication of negative results should be encour-
aged to provide a more balanced medical literature, and clinicians
should be aware of the existence of publication bias.PHARMACY ORAL
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OPTIMIZING THE ROLE OF TACROLIMUS BY ACHIEVING AND MAINTAIN-
ING TARGET LEVELS VIA A LOADING DOSE FOLLOWED BY A MAINTE-
NANCE DOSE AT EMORY HEALTHCARE
Ng, A., Wilson, N.M., Surati, M., Shah, K.S., Hutcherson, D.A. Emory
Healthcare, Atlanta, GA
Purpose: Graft-versus-host disease (GVHD) is a common compli-
cation associated with allogeneic hematopoietic stem cell transplants
(HSCT). Tacrolimus plays an integral role in GVHD prophylaxis.
At Emory Healthcare, the daily intravenous dose has been 0.03
mg/kg/day based on ideal body weight. Over the last two decades,
our target tacrolimus levels have gradually changed from 10 - 40
ng/mL to 6 - 12 ng/mL. However, our dosing has remained un-
changed. Due to results of a prior evaluation demonstrating that
the majority of our patients required dose reductions based on
drug levels, we implemented a 48 hour loading dose of 0.03 mg/
kg/day followed by a 0.02 mg/kg/day maintenance dose. We have
now performed an evaluation to assess the impact of this tacrolimus
dosing strategy compared to the previously studied cohort.
Method: A retrospective chart review was conducted in allogeneic
HSCT patients who received intravenous tacrolimus from May
2008 to March 2009. Data collected included height, weight, tacro-
limus doses on days - 2 through day 1 10, and tacrolimus levels on
days 0 through day1 10. This group was compared to the previously
studied cohort receiving the standard 0.03 mg/kg dose as a control.
Result: A total of 22 patients were studied. The control group of 14
patients demonstrated an average dose adjustment of 54% (25% -
96%) on days 5, 7, and 10. The study group remained at an approx-
imate average dose of 0.02 mg/kg/day for an average of 99% (50% -
200%) of the maintenance dose. Compared with the control group
which had 100% of patients achieving levels . 12 ng/mL during
days 1 through 10, the study group resulted in approximately 36%
of patients with supratherapeutic levels. The control group had
50%of patients with levels\6 ng/mL compared to 54% in the study
group.
